Respiratory medicines for children: current evidence, unlicensed use and research priorities

Abstract

This European Respiratory Society task force has reviewed the evidence for paediatric medicines in respiratory disease occurring in adults and children. We describe offlicence use, research priorities and ongoing studies.Off-licence and off-label prescribing in children is widespread and potentially harmful. Research areas in asthma include novel formulations and regimens, and individualised prescribing. In cystic fibrosis, future studies will focus on screened infants and robust outcome measures are needed. Other areas include new enzyme and antibiotic formulations and the basic defect. Research into pneumonia should include evaluation of new antibacterials and regimens, rapid diagnostic tests and, in pleural infection, antibiotic penetration, fibrinolytics and surveillance. In uncommon conditions, such as primary ciliary dyskinesia, congenital pulmonary abnormalities or neuromuscular disorders, drugs indicated for other conditions (e.g. dornase alfa) are commonly used and trials are needed. In neuromuscular disorders, the b-agonists may enhance muscle strength and are in need of evaluation. Studies of antibiotic prophylaxis, immunoglobulin and antifungal drugs are needed in immune deficiency.We hope that this summary of the evidence for respiratory medicines in children, highlighting gaps and research priorities, will be useful for the pharmaceutical industry, the paediatric committee of the European Medicines Agency, academic investigators and the lay public.

Medication adherence and the risk of severe asthma exacerbations: a systematic review

“…Another explanation is self-titrating of medications: patients show greater adherence to therapy with worse levels of control, thus positively influencing the MPR [27]. A third explanation could be the heterogeneity among asthma patients in treatment response: some patients reduce their prescribed controller medication without negative consequences [37], whereas other patients continue to have poor outcomes despite good adherence [60]. Additionally, there is no known dose of medication or duration of treatment.…”

Paediatric respiratory disease: past, present and future

“…Much work has been done, but many more questions are being developed [25]; above all, we need horizontal collaboration between groups of specialist paediatric pulmonologists, and vertical collaboration with adult respiratory colleagues. The future is with the young paediatric pulmonologists, and we must ensure that they have the best possible training; the pHERMES initiative bids fair to deliver this [26].…”

Pharmacology and Therapeutics of Bronchodilators

“…The European Respiratory Society task force, which has reviewed the evidence for pediatric medicines in respiratory disease, has advised that as-needed SABAs are the first choice for rescue treatment of acute asthma in children (Smyth et al, 2010). Regular, daily use of SABAs may cause deterioration of asthma and is not recommended.…”